Heart Failure Management
Introduction to Heart Failure
- Heart failure predominantly occurs in elderly patients with a mean age of approximately 75 years, often associated with comorbidities such as hypertension, renal insufficiency, chronic obstructive pulmonary disease, diabetes, stroke, arthritis, and anemia 1
- The European Society of Cardiology recommends that ACE inhibitors are effective and well-tolerated in elderly patients with heart failure due to left ventricular systolic dysfunction 1
Pharmacological Management
- ACE inhibitors are essential for managing heart failure and should be started at low doses, with gradual titration, monitoring renal function and potassium levels, with a strength of evidence level of I (high) 2, 3, 1
- Beta-blockers should be prescribed to all stable patients with current or prior symptoms of heart failure, starting with very low doses and titrating slowly, with careful monitoring of vital signs and clinical signs of congestion and perfusion, and a strength of evidence level of I (high) 2, 3, 1
- Diuretics are essential for managing fluid overload, preferring loop diuretics over thiazides in elderly patients, and monitoring for orthostatic hypotension and electrolyte imbalances 4, 5, 6, 1
- Aldosterone antagonists are recommended for advanced heart failure (NYHA III-IV) in addition to ACE inhibition and diuretics, with low-dose spironolactone (12.5-50mg daily) and monitoring for hyperkalemia 2, 1
- Digoxin is recommended for advanced heart failure (NYHA class III-IV) with systolic dysfunction, and for patients with atrial fibrillation and symptomatic heart failure, with careful monitoring of potassium levels 2, 1
- Antiarrhythmic drugs are only justified in patients with sustained and symptomatic ventricular tachycardias, where amiodarone should be the preferred agent 1
- Venodilators such as nitrates and the arterial dilator hydralazine should be administered with caution due to the risk of hypotension 1
- Hyperkalemia is more frequently observed in elderly patients with combination therapy of aldosterone antagonists and ACE inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) 1
Device Therapy
- Implantable cardioverter-defibrillators (ICDs) are indicated in patients with heart failure and potentially life-threatening ventricular arrhythmias 1
Monitoring and Follow-up
- Close monitoring is essential, with the first follow-up visit within 10 days after discharge, and regular evaluation of fluid intake and output, daily weight measurements, vital signs, and clinical signs of congestion and perfusion 1
- Regular assessment of serum electrolytes, urea nitrogen, and creatinine during active diuresis, with careful monitoring of renal function and potassium levels 4, 6
- The relief of symptoms may be the most important goal of treatment for many elderly patients 1
- Frailty and cognitive impairment should be assessed, and treatment decisions should focus on minimizing polypharmacy and optimizing medication regimens 7, 1
Special Considerations
- Patients with severe heart failure (NYHA Class III/IV), unknown etiology, bradycardia or low blood pressure, intolerance to low doses of beta-blockers, or previous discontinuation of beta-blockers due to symptoms should be referred to a heart failure specialist 2, 1
- Common pitfalls and considerations include avoiding NSAIDs, minimizing drug interactions, and carefully monitoring for orthostatic hypotension and electrolyte imbalances 2, 5, 1
- Pain management should be carefully considered, with acetaminophen recommended as the first-line analgesic, and avoidance of NSAIDs which can worsen heart failure through fluid retention and reduced renal function 5, 1
- Sleep disturbances can be managed with optimizing sleep hygiene, including maintaining a regular sleep schedule, timing diuretics earlier in the day, and avoiding caffeine and alcohol in the evening, with melatonin (1-2mg) or low-dose trazodone (25-50mg) as potential sleep aids 7, 8
- Pleural effusion management involves optimizing heart failure therapy, with careful monitoring of fluid intake and output, daily weight measurements, vital signs, and clinical signs of congestion and perfusion 4